CD14 promoter-159 polymorphism is associated with reduced risk of intestinal-type gastric cancer in a japanese population

Tomomitsu Tahara, Tomoyuki Shibata, Ichiro Hirata, Hiroshi Nakano, Tomiyasu Arisawa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Host genetic factors may play a key role in determining the long-term outcome of the Helicobacter pylori infection. Toll-like receptor 4 (TLR4) and CD14-mediated recognition of lipo-polysaccharide (LPS) is required for efficient recognition of Gram-negative bacterial infections. We investigated the effects of common polymorphisms of TLR4 Asp299Gly, Thr399Ile, and CD14 promoter-C159T on the risk of gastric cancer including its subtypes and clinicopathologic features. We also investigated the effects of these polymorphisms on histologic degree of H. pylori-induced gastritis. The study was performed in 149 gastric cancer (GC) cases [mean age 64.0 ± 12.4, M:F = 109:40] and 94 patients without evidence of GC (mean age 64.1 ± 12.3, M:F = 65:25, Peptic ulcer diseases = 43.6%, gastritis = 56.4%) as the control group. TLR4 Asp299Gly, Thr399Ile, and CD14 promoter-C159T were determined by PCR-RFLP in all the patients. Gastritis scores of non-cancerous gastric mucosa were assessed according to the updated Sydney system in H. pylori-positive subjects (n = 179). The frequencies of CD14-260 TT and T carrier were significantly lower in patents with intestinal-type gastric cancer than in controls (OR = 0.31; 95%CI = 0.12-0.78, OR = 0.38; 95%CI = 0.18-0.81, respectively). Compared to patients older than 61 years, the atrophy score in antrum was significantly lower in TT and CT patients. TLR4 Asp299Gly and Thr399Ile were not detected in all the patients. Our data suggests that CD14 promoter-159TT and T carrier were associated with a lower risk of developing gastric mucosal atrophy in H. pylori-infected patients of more than 61 years of age, and these genotypes may reduce the risk of intestinal-type gastric cancer.

Original languageEnglish
Pages (from-to)1508-1512
Number of pages5
JournalDigestive Diseases and Sciences
Volume54
Issue number7
DOIs
Publication statusPublished - 01-01-2009

Fingerprint

Intestinal Neoplasms
Stomach Neoplasms
Toll-Like Receptor 4
Helicobacter pylori
Gastritis
Population
Atrophy
Gram-Negative Bacterial Infections
Patents
Helicobacter Infections
Gastric Mucosa
Peptic Ulcer
Restriction Fragment Length Polymorphisms
Polysaccharides
Stomach
Genotype
Polymerase Chain Reaction
Control Groups

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Tahara, Tomomitsu ; Shibata, Tomoyuki ; Hirata, Ichiro ; Nakano, Hiroshi ; Arisawa, Tomiyasu. / CD14 promoter-159 polymorphism is associated with reduced risk of intestinal-type gastric cancer in a japanese population. In: Digestive Diseases and Sciences. 2009 ; Vol. 54, No. 7. pp. 1508-1512.
@article{f1ba4d96972a4ea784aba797c651a67e,
title = "CD14 promoter-159 polymorphism is associated with reduced risk of intestinal-type gastric cancer in a japanese population",
abstract = "Host genetic factors may play a key role in determining the long-term outcome of the Helicobacter pylori infection. Toll-like receptor 4 (TLR4) and CD14-mediated recognition of lipo-polysaccharide (LPS) is required for efficient recognition of Gram-negative bacterial infections. We investigated the effects of common polymorphisms of TLR4 Asp299Gly, Thr399Ile, and CD14 promoter-C159T on the risk of gastric cancer including its subtypes and clinicopathologic features. We also investigated the effects of these polymorphisms on histologic degree of H. pylori-induced gastritis. The study was performed in 149 gastric cancer (GC) cases [mean age 64.0 ± 12.4, M:F = 109:40] and 94 patients without evidence of GC (mean age 64.1 ± 12.3, M:F = 65:25, Peptic ulcer diseases = 43.6{\%}, gastritis = 56.4{\%}) as the control group. TLR4 Asp299Gly, Thr399Ile, and CD14 promoter-C159T were determined by PCR-RFLP in all the patients. Gastritis scores of non-cancerous gastric mucosa were assessed according to the updated Sydney system in H. pylori-positive subjects (n = 179). The frequencies of CD14-260 TT and T carrier were significantly lower in patents with intestinal-type gastric cancer than in controls (OR = 0.31; 95{\%}CI = 0.12-0.78, OR = 0.38; 95{\%}CI = 0.18-0.81, respectively). Compared to patients older than 61 years, the atrophy score in antrum was significantly lower in TT and CT patients. TLR4 Asp299Gly and Thr399Ile were not detected in all the patients. Our data suggests that CD14 promoter-159TT and T carrier were associated with a lower risk of developing gastric mucosal atrophy in H. pylori-infected patients of more than 61 years of age, and these genotypes may reduce the risk of intestinal-type gastric cancer.",
author = "Tomomitsu Tahara and Tomoyuki Shibata and Ichiro Hirata and Hiroshi Nakano and Tomiyasu Arisawa",
year = "2009",
month = "1",
day = "1",
doi = "10.1007/s10620-009-0793-5",
language = "English",
volume = "54",
pages = "1508--1512",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "7",

}

CD14 promoter-159 polymorphism is associated with reduced risk of intestinal-type gastric cancer in a japanese population. / Tahara, Tomomitsu; Shibata, Tomoyuki; Hirata, Ichiro; Nakano, Hiroshi; Arisawa, Tomiyasu.

In: Digestive Diseases and Sciences, Vol. 54, No. 7, 01.01.2009, p. 1508-1512.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CD14 promoter-159 polymorphism is associated with reduced risk of intestinal-type gastric cancer in a japanese population

AU - Tahara, Tomomitsu

AU - Shibata, Tomoyuki

AU - Hirata, Ichiro

AU - Nakano, Hiroshi

AU - Arisawa, Tomiyasu

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Host genetic factors may play a key role in determining the long-term outcome of the Helicobacter pylori infection. Toll-like receptor 4 (TLR4) and CD14-mediated recognition of lipo-polysaccharide (LPS) is required for efficient recognition of Gram-negative bacterial infections. We investigated the effects of common polymorphisms of TLR4 Asp299Gly, Thr399Ile, and CD14 promoter-C159T on the risk of gastric cancer including its subtypes and clinicopathologic features. We also investigated the effects of these polymorphisms on histologic degree of H. pylori-induced gastritis. The study was performed in 149 gastric cancer (GC) cases [mean age 64.0 ± 12.4, M:F = 109:40] and 94 patients without evidence of GC (mean age 64.1 ± 12.3, M:F = 65:25, Peptic ulcer diseases = 43.6%, gastritis = 56.4%) as the control group. TLR4 Asp299Gly, Thr399Ile, and CD14 promoter-C159T were determined by PCR-RFLP in all the patients. Gastritis scores of non-cancerous gastric mucosa were assessed according to the updated Sydney system in H. pylori-positive subjects (n = 179). The frequencies of CD14-260 TT and T carrier were significantly lower in patents with intestinal-type gastric cancer than in controls (OR = 0.31; 95%CI = 0.12-0.78, OR = 0.38; 95%CI = 0.18-0.81, respectively). Compared to patients older than 61 years, the atrophy score in antrum was significantly lower in TT and CT patients. TLR4 Asp299Gly and Thr399Ile were not detected in all the patients. Our data suggests that CD14 promoter-159TT and T carrier were associated with a lower risk of developing gastric mucosal atrophy in H. pylori-infected patients of more than 61 years of age, and these genotypes may reduce the risk of intestinal-type gastric cancer.

AB - Host genetic factors may play a key role in determining the long-term outcome of the Helicobacter pylori infection. Toll-like receptor 4 (TLR4) and CD14-mediated recognition of lipo-polysaccharide (LPS) is required for efficient recognition of Gram-negative bacterial infections. We investigated the effects of common polymorphisms of TLR4 Asp299Gly, Thr399Ile, and CD14 promoter-C159T on the risk of gastric cancer including its subtypes and clinicopathologic features. We also investigated the effects of these polymorphisms on histologic degree of H. pylori-induced gastritis. The study was performed in 149 gastric cancer (GC) cases [mean age 64.0 ± 12.4, M:F = 109:40] and 94 patients without evidence of GC (mean age 64.1 ± 12.3, M:F = 65:25, Peptic ulcer diseases = 43.6%, gastritis = 56.4%) as the control group. TLR4 Asp299Gly, Thr399Ile, and CD14 promoter-C159T were determined by PCR-RFLP in all the patients. Gastritis scores of non-cancerous gastric mucosa were assessed according to the updated Sydney system in H. pylori-positive subjects (n = 179). The frequencies of CD14-260 TT and T carrier were significantly lower in patents with intestinal-type gastric cancer than in controls (OR = 0.31; 95%CI = 0.12-0.78, OR = 0.38; 95%CI = 0.18-0.81, respectively). Compared to patients older than 61 years, the atrophy score in antrum was significantly lower in TT and CT patients. TLR4 Asp299Gly and Thr399Ile were not detected in all the patients. Our data suggests that CD14 promoter-159TT and T carrier were associated with a lower risk of developing gastric mucosal atrophy in H. pylori-infected patients of more than 61 years of age, and these genotypes may reduce the risk of intestinal-type gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=67349241894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349241894&partnerID=8YFLogxK

U2 - 10.1007/s10620-009-0793-5

DO - 10.1007/s10620-009-0793-5

M3 - Article

VL - 54

SP - 1508

EP - 1512

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 7

ER -